Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B -unfavorable genotype patients: Impaired viral kinetics and therapeutic response

Abstract

Carriers of the IL28B-favorable genotype were more likely to have superior innate immune response to IFN therapy compared with unfavorable genotypes, suggesting that the unfavorable genotype has aberrant baseline induction of innate immune response pathways resulting in impaired virologic response. IL28B genotype is associated with more rapid viral kinetics and improved treatment response outcomes independent of ISG expression.